<DOC>
	<DOCNO>NCT00555620</DOCNO>
	<brief_summary>The purpose study determine safe tolerable dos sunitinib give together either cisplatin capecitabine oxaliplatin capecitabine patient advance gastric cancer receive prior chemotherapy advance cancer</brief_summary>
	<brief_title>Study Of Sunitinib In Combination With Cisplatin/Capecitabine Or Oxaliplatin/Capecitabine In Patients With Advanced Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>confirm diagnosis stomach cancer advance stomach cancer stage IV adequate blood chemistry , blood count kidney function willing participate study requirement sign inform consent document prior chemotherapy stomach cancer advance stage excessive toxicity relate prior therapy pregnant breastfeed patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>